Hoth Therapeutics, Inc. (HOTH) Key Statistics & Financial Ratios

Hoth Therapeutics, Inc. (HOTH) — Price $0.80 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Hoth Therapeutics, Inc. (HOTH). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D.

Stock Data

Price$0.80
Market Cap$11M
Enterprise Value$2.7M
Beta0.60
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.97
Price / Book2.01
P/S0.00
EV/EBITDA-0.21
EV/Sales0.00
EV/FCF-0.26
P/FCF-1.00
Earnings Yield-80.91%
FCF Yield-100.36%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-199.23%
Return on Assets-138.98%
Return on Invested Capital-160.57%
Return on Capital Employed-160.57%

Financial Health

Current Ratio6.20
Quick Ratio6.20
Cash Ratio5.70
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA0.59
Interest Coverage0.00
Piotroski F-Score1
Altman Z-Score-11.74

Per-Share Data

Revenue per share0.00
Book Value per share0.40
Cash per share0.38
FCF per share-0.52
Tangible Book Value per share0.40
Dividend per share0.00

Related companies: ASBP · BCTX · CRIS · DARE · ENTO · FBLG · LEXX

Explore sector: Healthcare · Biotechnology

More sections of HOTH: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks